Current Report Filing (8-k)
January 08 2020 - 7:20AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 5, 2020
IMMUNIC, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
001-36201
|
56-2358443
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
1200 Avenue of the Americas, Suite
200
New York, NY 10036
USA
|
|
|
(Address of principal executive offices)
|
|
Registrant’s telephone number, including
area code: 49 89 250079460
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading symbol(s)
|
Name of each exchange
on which registered
|
Common Stock, $0.0001 par value
|
IMUX
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§ 240.12b2 of this chapter).
Emerging
growth company ý
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange
Act. Yes ý No ¨
Item 1.01. Entry into a Material Definitive Agreement.
On January 5, 2020, Immunic AG, under
the terms of its existing option and license agreement (the “Agreement”) with Daiichi Sankyo Co., Ltd. (“Daiichi
Sankyo”), exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things,
the option exercise grants Immunic AG the rights to Daiichi Sankyo’s patent application related to IMU-856. In connection
with the option exercise, Immunic, Inc. will pay a one-time upfront licensing fee to Daiichi Sankyo. Under the Agreement, Daiichi
Sankyo is also eligible to receive certain future development, approval and sales milestone payments, as well as royalties related
to IMU-856.
The foregoing summary of the Agreement
does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which
is filed as Exhibit 10.1 hereto and incorporated herein by reference.
Item 8.01 - Other Events.
On January 8, 2020, the Company posted
an updated corporate presentation on its website. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated
herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
+ Portions of this exhibit, marked by brackets, have been omitted
pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because they are both (i) not material
and (ii) would likely cause competitive harm to the registrant if publicly disclosed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Dated: January 8, 2020
|
Immunic, Inc.
|
|
|
|
|
By:
|
/s/ Daniel Vitt
|
|
|
Daniel Vitt
|
|
|
Chief Executive Officer
|
Immunic (NASDAQ:IMUX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immunic (NASDAQ:IMUX)
Historical Stock Chart
From Apr 2023 to Apr 2024